Novavax, Inc. (NVAX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.82B USD. 52-week range 6.20 to 13.39 USD. Data as of 2026-10-09.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the ...